On October 5, 2021 Philogen reported that Dario Neri, co-founder, CEO and CSO, is giving a presentation focused on Tripokin, a novel fusion protein capable of an exceptionally selective uptake at the tumor site(Press release, Philogen, OCT 5, 2021, View Source [SID1234590826]). The product contains two highly synergistic cytokine moieties (interleukin-2 and tumor necrosis factor) fused to the L19 antibody, specific to the alterantively-spliced EDB domain of fibronectin. In the seminar, Dario Neri is presenting the discovery and development of Tripokin towards clinical trials in patients with different types of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 5, 2021 GNS Healthcare (GNS), an artificial intelligence company creating in silico patients that simulate drug treatment at the individual patient level, reported a multi-year collaboration with Memorial Sloan Kettering Cancer Center (MSK) to leverage longitudinal multi-modal prostate cancer patient data and world class prostate cancer expertise with GNS’ Gemini in silico Prostate Cancer patient (Press release, Memorial Sloan-Kettering Cancer Center, OCT 5, 2021, View Source [SID1234590849]). The collaboration is one of four which MSK is undertaking through its new MSK Innovation Hub, a program that blends health tech innovators and MSK experts with the goal to speed the development of innovative products and businesses that have the potential to make a meaningful impact in the lives of people with cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This collaboration will address key questions for prostate cancer patients, including identifying subtypes of aggressive disease and discovering novel drug targets and drivers of patient response to an increasing array of therapeutics. These insights will enable the design of highly sophisticated clinical trials and generate evidence of comparative effectiveness between drugs and simulate treatment sequencing.

The work will build on the existing Gemini – The in silico Patient for Prostate Cancer developed in partnership with Tempus. Fueled by rich clinico-genomic data, specifically whole exome sequencing, RNAseq, patient treatment history, current treatments and associated lines of therapy and mortality, Gemini has already recapitulated known prognostic markers of overall survival and replicated the landmark Prostate Cancer Phase 3 LATITUDE Trial. Novel potential drivers of survival for metastatic castrate sensitive and castrate resistant prostate cancer patients have been discovered through Gemini’s hypothesis-free approach and will be validated and further understood through the collaboration with MSK.

"Collaborating with the MSK Innovation Hub will help to accelerate the discovery and development of new, more targeted and effective treatments for prostate cancer patients," said GNS CEO and Co-Founder, Colin Hill. "Simulating these in silico patient models allows us to understand what treatments work for which patients and why, improving clinical trial design and generating real-world evidence that maximizes the impact of drugs for patients. This has been a long road, but we are now at the point of being able to deliver true personalized treatments that work."

"The results generated from GNS’ transformative AI approach are compelling and I believe this ongoing collaboration will provide novel insights into prostate cancer that will directly improve patient care," said Howard I. Scher, MD, MSK medical oncologist and Head of the Biomarker Development Program.

MSK has institutional financial interests related to GNS associated with this collaboration.

On October 5, 2021 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that management will host a virtual event on October 12, 2021 at 4:30 p.m. ET to highlight clinical data from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of CTX110, its wholly-owned allogeneic chimeric antigen receptor T cell (CAR-T) investigational therapy targeting CD19, for the treatment of relapsed or refractory B-cell malignancies (Press release, CRISPR Therapeutics, OCT 5, 2021, View Source [SID1234590883]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast
To access the conference call, please dial +1 (866) 952-8559 (domestic) or +1 (785) 424-1743 (international) and reference the conference ID "CRISPR."

A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A webcast replay will be available on the CRISPR Therapeutics website after the event and will be archived for 14 days.

About CTX110
CTX110, a wholly owned program of CRISPR Therapeutics, is a healthy donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 19, or CD19. CTX110 is being investigated in the ongoing CARBON trial.

About CARBON
The ongoing Phase 1 single-arm, multi-center, open label clinical trial, CARBON, is designed to assess the safety and efficacy of several dose levels of CTX110 for the treatment of relapsed or refractory B-cell malignancies.

On October 5, 2021 Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, reported it will be presenting at the LD Micro Main Event, which is being held in-person and virtually from October 12th through 14th, 2021 (Press release, Scopus BioPharma, OCT 5, 2021, View Source [SID1234590807]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology, which Scopus announced in September 2021.

Alan Horsager, Ph.D., President — Immuno-Oncology of Scopus and President and Chief Executive Officer of Duet, will be presenting in-person on behalf of the company. Dr. Horsager’s presentation will be part of Track 4 on Tuesday, October 12, 2021 at 11:00 AM Eastern Time / 8:00 AM Pacific Time at the Luxe Sunset Bel-Air in Los Angeles. The presentation will also be available for viewing on-demand on the LD Micro conference website. Management will be available for one-on-one meetings to be held throughout the conference.

Investors interested in attending the conference in-person or virtually can register here. Once registered, you can request one-on-one meetings with the company through the conference website.

Dr. Horsager recently presented at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society during which he discussed data from two different studies that suggest that DUET-01 and DUET-02, two of Duet’s unique bifunctional oligonucleotides, can expand the reach and efficacy of cancer immunotherapies beyond certain standard-of-care treatments.

As previously announced, Scopus will also be presenting at The MicroCap Rodeo’s Fall Harvest Best Ideas Conference on Wednesday, October 6, 2021 at 5:00 PM Eastern Time. Investors interested in attending the virtual conference can register here.

About LD Micro Main Event

The 2021 LD Micro Main Event (XIV) will be held at the Luxe Sunset Bel-Air in Los Angeles from October 12th through 14th, 2021. The festivities run from 8:00 AM Pacific Time through 5:30 PM Pacific Time on October 12th and 13th with a morning session on October 14th. This three-day, investor conference is expected to feature around 150 companies, presenting for 25 minutes each, as well as several influential keynotes in-person. For more information, please contact [email protected].

About the Duet Platform

Duet Therapeutics integrates the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform. Olimmune was acquired by Scopus in June 2021. Duet is a wholly-owned subsidiary of Scopus.

The Duet Platform is comprised of three distinctive, complementary CpG-STAT3 inhibitors:

– RNA silencing CpG-STAT3siRNA ("DUET-01")
– Antisense CpG-STAT3ASO ("DUET-02")
– DNA-binding inhibitor CpG-STAT3decoy ("DUET-03")
DUET-01 is in a Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma. Duet expects to file two INDs for DUET-02 in Q4 2022 in genitourinary and head & neck cancers, with clinical Phase 1 trials beginning in Q1 2023 in the United States. Duet is also evaluating combination therapies with checkpoint inhibitors.

On October 5, 2021 T-Cure Bioscience, Inc., a privately held company focused on developing autologous T Cell Receptor Therapy (TCR-T) products for the treatment of solid tumors, and Atlas Antibodies AB, a Swedish company commercializing PrecisA monoclonal antibodies (mAb) for oncology targets, reported a collaborative agreement for the development, manufacture, and supply of CT83 (KK-LC-1) mAb(Press release, T-Cure Bioscience, OCT 5, 2021, View Source [SID1234590827]). These will be used to develop a diagnostic test to identify tumors that express KK-LC-1. Patients with KK-LC-1 positive tumors may be eligible inclusion in clinical trials of a KK-LC-1 targeted T-Cell therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Atlas Antibodies AB will provide all manufacturing and product supply for KK-LC-1 mAb for the companion diagnostic for clinical development. T-Cure is developing TCR-T therapeutics targeting Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) for gastric, triple negative breast cancer, cervical, lung and other KK-LC-1 positive cancers.

T-Cure plans to develop the companion diagnostic assay to identify KK-LC-1 positive cancer patients for inclusion in the company sponsor clinical trial planned for 2022.

"We are excited that Atlas Antibodies will supply high quality mAb shown to have superior specificity in recognizing KK-LC-1 in the patients’ samples." stated Gang Zeng, Ph.D., Chief Executive Officer at T-Cure Bioscience. "Developing an immnunohistochemistry (IHC) diagnostic tool is key to identify the right patient population to be treated by our KK-LC-1 specific TCR-T."

We are delighted to start this collaboration with T-Cure Bioscience. It reflects one of our new business models of deploying our highly validated monoclonals through contract manufacturing in which both parties are enabled to focus on their core competencies," stated Nille Klæbel, Chief Executive Officer at Atlas Antibodies. "We are convinced that this creates a win-win situation for both parties.